Quantitative Evaluation of Progression of Retinal Vascularization After 60 Weeks Postmenstrual Age in Infants Treated With Bevacizumab.

Background And Objective: To investigate the progression of retinal vascularization after 60 weeks postmenstrual age (PMA) in eyes treated with intravitreal bevacizumab (IVB).

Patients And Methods: Twenty-seven eyes that were treated with IVB and underwent two consecutive fluorescein angiographies (FA) after 60 weeks PMA. Horizontal disc diameter (DD), disc-to-fovea (DF) distance, and length of temporal retinal vascularization (LTRV) were measured in pixels on the two consecutive angiograms.

Results: Mean age at first and final FA sessions were 77.7 ± 15.7 and 168.0 ± 49.0 weeks PMA, respectively. The DF/DD ratio was 3.30 ± 0.46 and 3.16 ± 0.46 in the first and final FAs ( = 0.001), respectively. The LTRV/DD ratio was 13.38 ± 2.12 and 13.15 ± 2.13 in the first and final FAs ( = 0.027), respectively. The LTRV/DF ratio was 4.06 ± 0.39 and 4.17 ± 0.42, respectively ( = 0.032).

Conclusion: Temporal retinal vascularization did not progress despite an average follow-up of 90 weeks in pixel units and DD. .